Cosmos Health Q1 revenue +31% to $17.93M; net loss widens to $2.81M

Cosmos Health Inc.

2026-Q1 EPS reported -$0.06 revenue$17,927,892

Q1 revenue $17.93M, up 31% YoY from $13.71M; adjusted revenue $18.40M (+34.2%).
Net loss of ($2.81M) vs ($0.82M) in Q1 2025, driven by $1.15M in non-cash items.
Total liabilities reduced $4.5M (-9.6%) to $42.54M; stockholders' equity up 7.6% to $19.83M.
Adjusted EBITDA near breakeven at ($229,596); company expects positive EBITDA as revenues scale.
Strategic investments in U.S. expansion via 18 Series platform; Q2 momentum continues.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cosmos Health Inc. reported first quarter ended March 31, 2026 results: revenue $17.93 million, net income ($2.81 million).

Period: first quarter ended March 31, 2026
Revenue: $17.93 million
Net income: ($2.81 million)
Result: reported results

Exact text from the filing

added at CosmoFarm, growing Sky Premium Life order activity across multiple markets, and expanded contract manufacturing agreements at Cana Laboratories. · Revenue was $17.93 million, an increase of 30.7% from $13.71 million in Q1 2025, reflecting strong sales momentum across all core divisions. ○ Adjusted revenue was $18.40 million, up 34.2% year-over-year,

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Cosmos Health Inc. filing history →

Source: SEC EDGAR

accession 0001477932-26-003403

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.